Fundamental Analysis of CYMABAY THERAPEUTICS INC(NASDAQ:CBAY) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to CBAY. CBAY was compared to 198 industry peers in the Pharmaceuticals industry. While CBAY seems to be doing ok healthwise, there are quite some concerns on its profitability. CBAY is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CBAY has reported negative net income.

In the past year CBAY has reported a negative cash flow from operations.

CBAY had negative earnings in each of the past 5 years.

CBAY had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -24.24%, CBAY perfoms like the industry average, outperforming 59.20% of the companies in the same industry.

Looking at the Return On Equity, with a value of -36.05%, CBAY is in the better half of the industry, outperforming 64.18% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-24.24%
ROE	-36.05%
ROIC	N/A

ROA(3y)-47.81%

ROA(5y)-45.31%

ROE(3y)-132.2%

ROE(5y)-97.5%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CBAY so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CBAY does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for CBAY has been increased compared to 1 year ago.

Compared to 5 years ago, CBAY has more shares outstanding

CBAY has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 12.87 indicates that CBAY is not in any danger for bankruptcy at the moment.

The Altman-Z score of CBAY (12.87) is better than 89.05% of its industry peers.

CBAY has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.

CBAY has a Debt to Equity ratio of 0.34. This is in the lower half of the industry: CBAY underperforms 60.20% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.34
Debt/FCF	N/A
Altman-Z	12.87

ROIC/WACCN/A

WACC8.71%

2.3 Liquidity

A Current Ratio of 10.96 indicates that CBAY has no problem at all paying its short term obligations.

CBAY's Current ratio of 10.96 is amongst the best of the industry. CBAY outperforms 87.56% of its industry peers.

A Quick Ratio of 10.96 indicates that CBAY has no problem at all paying its short term obligations.

With an excellent Quick ratio value of 10.96, CBAY belongs to the best of the industry, outperforming 87.56% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	10.96
Quick Ratio	10.96

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CBAY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.83%, which is quite good.

EPS 1Y (TTM)19.83%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-16.67%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 34.83% on average over the next years. This is a very strong growth

CBAY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 87.60% yearly.

EPS Next Y-50.27%

EPS Next 2Y-4.63%

EPS Next 3Y18.9%

EPS Next 5Y34.83%

Revenue Next Year-62.23%

Revenue Next 2Y92.15%

Revenue Next 3Y99.83%

Revenue Next 5Y87.6%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CBAY. In the last year negative earnings were reported.

Also next year CBAY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CBAY's earnings are expected to grow with 18.90% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-4.63%

EPS Next 3Y18.9%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CBAY does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CYMABAY THERAPEUTICS INC

NASDAQ:CBAY (3/21/2024, 8:15:47 PM)

After market: 32.48 0 (0%)

32.48

+0.01 (+0.03%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap3.73B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-24.24%
ROE	-36.05%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.07

Health

		Industry Rank	Sector Rank
Debt/Equity	0.34
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	10.96
Quick Ratio	10.96
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)19.83%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-50.27%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CYMABAY THERAPEUTICS INC (CBAY)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens